National consensus on the diagnosis, risk stratification and treatment of patients with pulmonary embolism;Consenso nacional sobre el diagnóstico, estratificación de riesgo y tratamiento de los pacientes con tromboembolia pulmonar

Archivos de Bronconeumologia

Volumn 49, Issue 12, 2013, Pages 534-547

  Uresandi, Fernando ^a   Monreal, Manuel ^b   García Bragado, Ferrán ^c   Domenech, Pere ^d   Lecumberri, Ramón ^e   Escribano, Pilar ^f   Zamorano, José Luis ^g   Jiménez, Sonia ^h   Ruiz Artacho, Pedro ⁱ   Lozano, Francisco ^d   Romera, Antonio ^j   Jiménez, David ^g  

^a HOSPITAL DE CRUCES   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^j HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT THERAPY; ARTICLE; CONSENSUS; DIAGNOSTIC TEST; HUMAN; LUNG EMBOLISM; RISK ASSESSMENT; ACUTE DISEASE; ALGORITHM; ASYMPTOMATIC DISEASE; BLEEDING; CARDIOGENIC SHOCK; CHRONIC DRUG ADMINISTRATION; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CLINICAL DECISION MAKING; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DEEP VEIN THROMBOSIS; DEVICE THERAPY; DIAGNOSTIC ACCURACY; DRUG CONTRAINDICATION; ECHOGRAPHY; HOSPITAL DISCHARGE; HOSPITAL MORTALITY; HYPERCOAGULABILITY; INCIDENTAL FINDING; INTRACARDIAC THROMBOSIS; LABORATORY TEST; LOW RISK PATIENT; LUNG HEMODYNAMICS; LUNG SCINTISCANNING; MAGNETIC RESONANCE ANGIOGRAPHY; MOBILIZATION; MORTALITY RATE; MULTIDETECTOR COMPUTED TOMOGRAPHY; PATHOGENESIS; PATIENT ASSESSMENT; PRACTICE GUIDELINE; PROGNOSIS; RECURRENCE RISK; RISK FACTOR; RISK MANAGEMENT; SENSITIVITY AND SPECIFICITY; SURGICAL THROMBECTOMY; SYMPTOM; SYSTEMIC THERAPY; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY;

ALGORITHMS; ANTICOAGULANTS; DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; EMBOLECTOMY; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; NEOPLASMS, UNKNOWN PRIMARY; POSTOPERATIVE COMPLICATIONS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PULMONARY EMBOLISM; RISK; THROMBOPHILIA; VENA CAVA FILTERS;

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; D DIMER; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NEW DRUG;

EID: 84889092393     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2013.10.008     Document Type: Article

References (62)

1. Kearon C., Akl E.A., Comerota A.J., Prandoni P., Bounameaux H., Goldhaber S.Z., et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:419S-494S.
2. National Institute for Health and Clinical Excellence. CG144 venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. NICE clinical guidelines 2012 [acceso Feb 2013]. Disponible en: http://www.nice.org.uk/guidance/cg.
3. Schünemann H.J., Jaeschke R., Cook D.J., Bria W.F., El-Solh A.A., Ernst A., et al. An official ATS statement: Grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 2006, 174:605-614. ATS Documents Development and Implementation Committee.
4. Roy P.M., Meyer G., Vielle B., le Gall C., Verschuren F., Carpentier F., et al. Appropriateness of diagnostic management and outcomes of suspected pulmonary embolism. Ann Intern Med 2006, 144:157-164. EMDEPU Study Group.
5. Carrier M., Righini M., Djurabi R.K., Huisman M.V., Perrier A., Wells P.S., et al. VIDAS D-dimer in combination with clinical pre-test probability to rule out pulmonary embolism. A systematic review of management outcome studies. Thromb Haemost 2009, 101:886-892.
6. Mos I.C., Klok F.A., Kroft L.J., de Roos A., Dekkers O.M., Huisman M.V. Safety of ruling out acute pulmonary embolism by normal computed tomography in patients with an indication for computed tomography: Systematic review and meta-analysis. J Thromb Haemost 2009, 7:1491-1498.
7. Stein P.D., Fowler S.E., Goodman L.R., Gottschalk A., Hales C.A., Hulla R.D., et al. Multidetector computed tomography for acute pulmonary embolism. N Engl J Med 2006, 354:2317-2327. PIOPED II Investigators.
8. Radiological Society of North America 2013 [acceso Feb 2013). Disponible en: http://www.radiologyinfo.org/.
9. Leung A.N., Bull T.M., Jaeschke R., Lockwood C.J., Boiselle P.M., Hurwitz L.M., et al. American Thoracic Society documents: An official American Thoracic Society/Society of Thoracic Radiology Clinical Practice Guideline Evaluation of Suspected Pulmonary Embolism in Pregnancy. Radiology 2012, 262:635-646. ATS/STR Committee on Pulmonary Embolism in Pregnancy.
10. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA 1990, 263:2753-2759. The PIOPED Investigators.
11. Stein P.D., Chenevert T.L., Fowler S.E., Goodman L.R., Gottschalk A., Hales C.A., et al. Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism: a multicenter prospective study (PIOPED III). Ann Intern Med 2010, 152:434-443. PIOPED III (Prospective Investigation of Pulmonary Embolism Diagnosis III) Investigators.
12. Goldhaber S.Z., Visani L., de Rosa M. Acute pulmonary embolism: Clinical outcomes in the International Cooperative Pulmonary Embolism Registry. Lancet 1999, 353:24-27.
13. Jiménez D., Aujesky D., Yusen R.D. Risk stratification of normotensive patients with acute pulmonary embolism. Br J Haematol 2010, 151:415-424.
14. Aujesky D., Obrosky D.S., Stone R.A., Auble T.E., Perrier A., Cornuz J., et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005, 172:1041-1046.
15. Jiménez D., Aujesky D., Moores L., Gómez V., Lobo J.L., Uresandi F., et al. Simplification of the Pulmonary Embolism Severity Index for prognosticating patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010, 170:1383-1389. for the RIETE investigators.
16. Sanchez O., Trinquart L., Colombet I., Durieux P., Huisman M.V., Chatellier G., et al. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: A systematic review. Eur Heart J 2008, 29:1569-1577.
17. Kang D.K., Thilo C., Schoepf J., Barraza J.M., Nance J.W., Bastarrika G., et al. CT signs of right ventricular dysfunction: Prognostic role in acute pulmonary embolism. J Am Coll Cardiol Img 2011, 4:841-849.
18. Becattini C., Agnelli G., Vedovati M.C., Pruszczyk P., Casazza F., Grifoni S., et al. Multidetector computed tomography for acute pulmonary embolism: Diagnosis and risk stratification in a single test. Eur Heart J 2011, 32:1657-1663.
19. Becattini C., Vedovati M.C., Agnelli G. Prognostic value of troponins in acute pulmonary embolism. Circulation 2007, 116:427-433.
20. Jiménez D., Uresandi F., Otero R., Lobo J.L., Monreal M., Martí D., et al. Troponin-based risk stratification of patients with nonmassive pulmonary embolism: Systematic review and metaanalysis. Chest 2009, 136:974-982.
21. Binder L., Pieske B., Olschewski M., Geibel A., Klostermann B., Reiner C., et al. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation 2005, 112:1573-1579.
22. Klok F.A., Mos I.C., Huisman M.V. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: A systematic review and meta-analysis. Am J Respir Crit Care Med 2008, 178:425-430.
23. Jiménez D., Aujesky D., Díaz G., Monreal M., Otero R., Martí D., et al. Prognostic significance of concomitant deep vein thrombosis in patients presenting with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med 2010, 181:983-991. and the RIETE investigators.
24. Trujillo-Santos J., Schellong S., Falga C., Zorrilla V., Gallego P., Barrón M., et al. Low-molecular-weight or unfractionated heparin in venous thromboembolism: The Influence of renal function. Am J Med 2013, 126:425-434. RIETE Investigators.
25. Quinlan D.J., McQuillan A., Eikelboom J.W. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism. A meta-analysis of randomized, controlled trials. Ann Intern Med 2004, 140:175-183.
26. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003, 349:1695-1702. The Matisse Investigators.
27. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510. The EINSTEIN Investigators.
28. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012, 366:1287-1297. The EINSTEIN-PE Investigators.
29. Aujesky D., Roy P.M., Verschuren F., Righini M., Osterwalder J., Egloff M., et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: An international, open-label, randomised, non-inferiority trial. Lancet 2011, 378:41-48.
30. Agnelli G., Büller H.R., Cohen A., Curto M., Gallus A.S., Johnson M., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013, 369:799-808. for the AMPLIFY Investigators.
31. Anderson C.M., Overend T.J., Godwin J., Sealy C., Sunderji A. Ambulation after deep vein thrombosis: A systematic review. Physioter Can 2009, 61:133-140.
32. Jiménez D., Aujesky D., Moores L., Gómez V., Martí D., Briongos S., et al. Combinations of prognostic tools for identification of high-risk normotensive patients with acute symptomatic pulmonary embolism. Thorax 2011, 66:75-81.
33. The Urokinase Pulmonary Embolism Trial: A national cooperative study. Circulation 1973, 47(2 Suppl):II1-II108.
34. Jaff M.R., Archer S.L., Cushman M., Goldenberg N., Goldhaber S.Z., Jenkins S., et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: A scientific statement from the American Heart Association. Circulation 2011, 123:1788-1830. on behalf of the American Heart, Association Council on Cardiopulmonary CC, Perioperative and Resuscitation, Council on Peripheral Vascular Disease, and Council on Arteriosclerosis, Thrombosis and Vascular Biology.
35. Konstantinides S., Geibel A., Heusel G., Heinrich F., Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002, 347:1143-1150. Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators.
36. Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism, who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the pulmonary embolism thrombolysis (PEITHO) trial. Am Heart J 2012, 163:33-38. The Steering Committe, on behalf of the PEITHO investigators.
37. Decousus H., Leizorovicz A., Parent F., Page Y., Tardy B., Girard P., et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep vein thrombosis. N Engl J Med 1998, 338:409-415.
38. Meneveau N., Séronde M.F., Blonde M.C., Legalery P., Didier-Petit K., Briand F., et al. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest 2006, 129:1043-1050.
39. Carrier M., Righini M., Wells P.S., Perrier A., Anderson D.R., Rodger M.A., et al. Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies. J Thromb Haemost 2010, 8:1716-1722.
40. O'Connell C., Razavi P., Ghalichi M., Boyle S., Vasan S., Mark L., Caton A., et al. Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning. J Thromb Haemost 2011, 9:305-311.
41. Boutitie F., Pinede L., Schulman S., Agnelli G., Raskob G., Julian J., et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ 2011, 342:d3036.
42. Iorio A., Kearon C., Filippucci E., Marcucci M., Macura A., Pengo V., et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: A systematic review. Arch Intern Med 2010, 170:1710-1716.
43. Ruíz-Giménez N., Suárez C., González R., Nieto J.A., Todolí J.A., Samperiz A.L., et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008, 100:26-31. RIETE Investigators.
44. Baglin T., Douketis J., Tosetto A., Marcucci M., Cushman M., Kyrle P., et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost 2010, 8:2436-2442.
45. Palareti G., Cosmi B., Legnani C., Tosetto A., Brusi C., Iorio A., et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006, 355:1780-1789. PROLONG Investigators.
46. Carrier M., Rodger M.A., Wells P.S., Righini M., Gal L.E.G. Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: A systematic review and meta-analysis. J Thromb Haemost 2011, 9:1119-1125.
47. Murin S., Romano P.S., White R.H. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost 2002, 88:407-414.
48. Ho W.K., Hankey G.J., Quinlan D.J., Eikelboom J.W. Risk of recurrent venous thromboembolism in patients with common thrombophilia: A systematic review. Arch Intern Med 2006, 166:729-736.
49. Tosetto A., Iorio A., Marcucci M., Baglin T., Cushman M., Eichinger S., et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism. A proposed prediction score (DASH). J Thromb Haemost 2012, 10:1019-1025.
50. Eichinger S., Heinze G., Jandeck L.M., Kyrle P.A. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: The Vienna prediction model. Circulation 2010, 121:1630-1636.
51. Rodger M.A., Kahn S.R., Wells P.S., Anderson D.A., Chagnon I., le Gal G., et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008, 179:417-426.
52. Kearon C., Ginsberg J.S., Kovacs M.J., Anderson D.R., Wells P., Julian J.A., et al. Comparison of low-Intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003, 349:631-639. Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators.
53. Ridker P.M., Goldhaber S.Z., Danielson E., Rosenberg Y., Eby C.S., Deitcher S.R., et al. Long-term, low-intensity warfarin therapy for the prevention recurrent venous thromboembolism. N Engl J Med 2003, 348:1425-1434. PREVENT Investigators.
54. Agnelli G., Büller H.R., Cohen A., Curto M., Gallus A.S., Johnson M., et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013, 368:699-708. for the AMPLIFY-EXT Investigators.
55. Schulman S., Kearon C., Kakkar A.K., Schellong S., Eriksson H., Baanstra D., et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013, 368:709-718. for the RE-MEDY and the RE-SONATE Trials Investigators.
56. Becattini C., Agnelli G., Schenone A., Eichinger S., Bucherini E., Silingardi M., et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012, 366:1959-1967. WARFASA Investigators.
57. Brighton T.A., Eikelboom J.W., Mann K., Mister R., Gallus A., Ockelford P., et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012, 367:1979-1987. ASPIRE Investigators.
58. Nijkeuter M., Hovens M.M.C., Davidson B.L., Huisman M.V. Resolution of thromboemboli in patients with acute pulmonary embolism. Chest 2006, 129:192-197.
59. Nijkeuter M., Söhne M., Tick L.W., Kamphuisen P.W., Kramer M.H., Laterveer L., et al. The natural course of hemodynamically stable pulmonary embolism. Chest 2007, 131:517-523. Christopher Study Investigators.
60. Pengo V., Lensing A.W., Prins M.H., Marchiori A., Davidson B.L., Tiozzo F., et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004, 350:2257-2264. Thromboembolic Pulmonary Hypertension Study Group.
61. Jiménez D., Gaudó J., Sueiro A. Chronic thromboembolic pulmonary hypertension. Risk factors. Arch Bronconeumol 2009, 45:10-13.
62. Van Doormaal F.F., Terpstra W., van der Griend R., Prins M.H., Nijziel M.R., van de Ree M.A., et al. Is extensive screening for cancer in idiopathic venous thromboembolism warranted?. J Thromb Haemost 2011, 9:79-84.